DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...

Dr. Mark Velleca is currently the CEO and Board Chair of Black Diamond Therapeutics (BDTX) and also serves as Board Chair of Myeloid Therapeutics. Mark served as CEO of G1 Therapeutics (GTHX) until ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

Goldman Sachs analyst Richard Law initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $30 price target The company’s lead asset, VK2735, is a dual GLP-1/GIP agonist being ...

About NeuroSense NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative ...

Endlyz Therapeutics has launched from stealth, unveiling its pipeline of small molecule modulators designed to restore lysosomal function in Parkinson’s disease (PD) and other neurodegenerative ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Summit Therapeutics (NASDAQ:SMMT) stock is up 347% in the last year, providing strong gains for shareholders.

Spark Therapeutics, a gene therapy pioneer based in Philadelphia’s University City, is laying off 337 employees, more than half its workforce, as part of a restructuring by its owner, Swiss ...

Biotech startup Prazer Therapeutics has completed a Series B funding round. The secured funds will be used for new drug research and development and global commercialization. This investment round ...

Canaccord Genuity analyst John Newman maintained a Buy rating on Marker Therapeutics (MRKR – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $1.23.